We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-22.77%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.72B
AUM Growth
-$1.36B
Cap. Flow
-$888M
Cap. Flow %
-51.56%
Top 10 Hldgs %
32.97%
Holding
299
New
73
Increased
48
Reduced
40
Closed
96

Top Buys

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$37.8M
2
GH icon
Guardant Health
GH
+$19.9M
3
LUNG icon
Pulmonx
LUNG
+$15.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.5M
5
LYRA
LYRA THERAPEUTICS INC
LYRA
+$11.2M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$18M
2
CCCC icon
C4 Therapeutics
CCCC
+$15.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13.5M
4
ICUI icon
ICU Medical
ICUI
+$12.8M
5
CNVY
Convey Health Solutions Holdings, Inc.
CNVY
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 32.95%
2 Industrials 0.3%
3 Consumer Staples 0.27%
4 Materials 0.11%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
151
DELISTED
Esperion Therapeutics
ESPR
$1.35M 0.08%
+212,123
New +$1.2M
SDGR icon
152
Schrodinger
SDGR
$1.4B
$1.32M 0.08%
50,000
– –
SKIN icon
153
CALL
SkinHealth Systems
SKIN
$87.2M
$1.29M 0.07%
100,000
-424,100
-81% -$5.68M
LHDX
154
DELISTED
Lucira Health, Inc. Common Stock
LHDX
$1.28M 0.07%
690,663
+3,450
+0.5% +$8.38K
RDUS
155
PUT
DELISTED
Radius Health, Inc.
RDUS
$1.24M 0.07%
+119,200
New +$887K
VRDN icon
156
Viridian Therapeutics
VRDN
$2.59B
$1.22M 0.07%
105,460
– –
XENE icon
157
Xenon Pharmaceuticals
XENE
$6.27B
$1.22M 0.07%
40,002
+25,000
+167% +$756K
ADPT icon
158
Adaptive Biotechnologies
ADPT
$3.97B
$1.21M 0.07%
150,000
– –
VSTM icon
159
Verastem
VSTM
$628M
$1.17M 0.07%
+83,689
New +$1.33M
IMUX icon
160
PUT
Immunic
IMUX
$211M
$1.16M 0.07%
33,550
+3,550
+12% +$227K
RLMD icon
161
PUT
Relmada Therapeutics
RLMD
$493M
$1.16M 0.07%
+61,000
New +$1.33M
BLU
162
DELISTED
BELLUS Health Inc.
BLU
$1.13M 0.07%
122,000
-268,097
-69% -$2.19M
MDVL
163
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$1.09M 0.06%
14,282
– –
OBIO icon
164
Orchestra BioMed
OBIO
$260M
$1.04M 0.06%
104,026
– –
HZNP
165
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$1.03M 0.06%
+12,900
New +$1.22M
LQDA icon
166
PUT
Liquidia Corp
LQDA
$7.12B
$1.02M 0.06%
+234,700
New +$1.21M
PHAT icon
167
Phathom Pharmaceuticals
PHAT
$710M
$864K 0.05%
102,328
– –
GOSS icon
168
PUT
Gossamer Bio
GOSS
$87.4M
$837K 0.05%
+100,000
New +$775K
LONA
169
LeonaBio Inc
LONA
$72M
$818K 0.05%
26,813
-7,134
-21% -$654K
PLRX icon
170
CALL
Pliant Therapeutics
PLRX
$65M
$801K 0.05%
+100,000
New +$640K
CMRX
171
DELISTED
Chimerix, Inc.
CMRX
$801K 0.05%
+384,905
New +$1.24M
SNAX
172
DELISTED
Stryve Foods, Inc. Class A Common Stock
SNAX
$705K 0.04%
+53,333
New +$868K
GOSS icon
173
Gossamer Bio
GOSS
$87.4M
$677K 0.04%
80,878
-7,051
-8% -$54.6K
CLVS
174
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$511K 0.03%
+284,000
New +$419K
BPMC
175
PUT
DELISTED
Blueprint Medicines
BPMC
$505K 0.03%
+10,000
New +$586K
5 6
7
8 9

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q2 2022 Portfolio in Review

As of Q2 2022, Pura Vida Investments held 299 positions worth $1.72B, down 44% from $3.08B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Pura Vida Investments withdrew a net $888M in Q2 2022, closing 96 positions and reducing 40 holdings. Its most notable exit was C4 Therapeutics, an estimated $15.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 24% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Pura Vida Investments opened a new position in Glaukos worth $36.2M.

  • Pura Vida Investments's largest Q2 2022 buy was Glaukos: 796,600 shares worth $36.2M.
  • Pura Vida Investments added most to Guardant Health in Q2 2022, an estimated $19.9M increase.
  • Pura Vida Investments's biggest Q2 2022 reduction was Vertex Pharmaceuticals, cutting an estimated $18M.
  • Pura Vida Investments fully exited C4 Therapeutics in Q2 2022, selling an estimated $15.2M.
  • Pura Vida Investments's ten largest holdings make up 33% of its $1.72B portfolio in Q2 2022.
  • Pura Vida Investments opened 73 new positions and closed 96 in Q2 2022.
  • Pura Vida Investments's portfolio value fell 44% quarter-over-quarter to $1.72B.

Based on Pura Vida Investments's 13F filing for Q2 2022, filed 15 Aug 2022.